News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ICRC-Weyer Ready for Increase in Advanced Therapy Trials


9/25/2012 11:01:28 AM

September 2012 -- CRC-Weyer’s recent participation in the NanoKTN meeting on September 5th proved to be informative and successful. Two members of the ICRC-Weyer team, Christina Richter and Dr. Iris Hardewig, attended the event which took place at the British Embassy in Berlin. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in discussions on potential co-operations with the other participants.

The event demonstrated the rapid and versatile development in the area of regenerative medicine. A wave of ATMP (Advanced Therapy Medicinal Product) registrations is to be expected in the coming 10 to 15 years. As a medium-sized CRO offering specialized and flexible services to small biotech companies, ICRC-Weyer is prepared to support this promising development. The engaged discussions of our team members with different participating companies show that there is a lively interest in high quality clinical services in the area of regenerative medicine, with the 7th Framework Programme (FP7) initiated by the EU providing just one potential source of funding for the early clinical development of advanced therapies. The networking event was hosted by UK Nanotechnology Knowledge Transfer Network (NanoKTN) and BioTOP Berlin-Brandenburg.

The meeting is designed to bring a selection of the UK’s leading companies and academics developing nano-structured materials and biomaterials for use in tissue engineering and regenerative medicine, to meet with centres of research excellence in Berlin.

About FP7: The Seventh Framework Programme for Research and Technological Development (FP7) is the EU's main instrument for funding research in Europe. The program supports research in selected priority areas - the aim being to make, or keep, the EU as a world leader in those sectors.

About ICRC-Weyer:

ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process. ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES